bioAffinity Technologies Notified of Nasdaq Non-Compliance (Bid Price)

What Happened

• bioAffinity Technologies, Inc. announced on July 30, 2026 that Nasdaq's Listing Qualifications Staff determined the company's bid price closed below $1.00 per share for 30 consecutive business days (June 16, 2026 through July 29, 2026), meaning it does not meet Nasdaq Listing Rule 5550(a)(2).
• Because the company completed a 1-for-30 reverse stock split on September 19, 2025, Nasdaq informed the company it is not eligible for the normal 180-calendar-day compliance period under Rule 5810(c)(3)(A)(iv).
• The company plans to submit an appeal to Nasdaq on August 6, 2026; filing the appeal will stay any delisting or suspension pending the Nasdaq Hearings Panel decision.

Key Details

• Nasdaq determination date: July 30, 2026; non-compliant bid-price period: June 16–July 29, 2026 (30 business days).
• Reverse split: 1-for-30 effective September 19, 2025 (causes ineligibility for the standard 180-day cure period).
• Company action: intends to appeal to Nasdaq on August 6, 2026; appeal stays delisting/suspension until Panel decision.
• Rules cited: Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid) and Rule 5810(c)(3)(A)(iv) (reverse-split ineligibility).

Why It Matters

• This notice signals a real risk that bioAffinity's common stock could be suspended or delisted from The Nasdaq Capital Market if the company cannot demonstrate compliance or obtain an extension from the Nasdaq Hearings Panel.
• Delisting risk can reduce liquidity, limit investor access, and affect the company's visibility and ability to raise capital; the appeal temporarily prevents immediate suspension but offers no guarantee of a favorable outcome.
• Investors should note the company’s planned appeal date and watch for the Panel’s decision and any subsequent disclosures about steps to regain compliance.